Table 1.
Patient characteristics
| N | ALF | LC |
|---|---|---|
| 5 | 22 | |
| Recipient related factors | ||
| Age at OLT | 29 (27–46) | 53 (47–56) |
| Age at start of vaccine | 36 (30–51) | 56 (49–59) |
| Sex (M) | 1 (20 %) | 19 (86 %) |
| HBsAg at OLT | 0.7 (0–1) | 2000 (100–2000) |
| HBV DNA at OLT (≥3.7) | 0 (0 %) | 8 (36 %) |
| MELD at OLT | 21 [19–21] | 15 [9–18] |
| HCC at OLT (+) | 0 (0 %) | 15 (68 %) |
| Donor related factors | ||
| Age at OLT | 32 (27–44) | 46 (31–49) |
| Sex (M) | 4 (80 %) | 9 (40 %) |
| ABO (identical) | 4 (80 %) | 12 (54 %) |
| Blood relation (no) | 0 (0 %) | 8 (36 %) |
| Anti-HBs antibody (>100) | 1 (20 %) | 9 (40 %) |
| Anti-HBc antibody (+) | 1 (20 %) | 11 (50 %) |
| Anti-HBc(+)/anti-HBs(+) | 1 (20 %) | 10 (45 %) |
| Anti-HBc(+)/anti-HBs(−) | 0 (0 %) | 1 (4 %) |
| Anti-HBc(−)/anti-HBs(+) | 0 (0 %) | 0 (0 %) |
ALF acute liver failure, LC liver cirrhosis, OLT orthotopic liver transplantation, MELD Model for End-stage Liver Disease, HCC hepatocellular carcinoma